Dr Amol Akhade· @SuyogCancer · X·· 1 天前评分70
正文 · 原文
Saffron trial. Osimertinib plus savolitinib against chemo, post progression on osimertinib for advanced NSCLC with egfr mutation and met amplification /overexpression. @OncoAlert @myESMO #esmo26
117 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Dr Amol Akhade · x.com